Dual-antigen T-cell engagement demonstrates encouraging clinical activity in advanced prostate cancer.
At #SITC26, Laura Graham, MD of @CUDeptMedicine presents phase 1 results showing substantial PSA reductions and a manageable safety profile with combined KLK2 and PSMA targeting. #MoffittSITC26